Anavex Life Sciences (AVXL) Cash from Operations (2010 - 2025)
Anavex Life Sciences recorded quarterly Cash from Operations of 7151000.0 in Q4 2025, up 16.89% quarter-over-quarter from 8604000.0 in Q3 2025, and up 41.0% year-over-year from 5071690.56 in Q4 2024.
Anavex Life Sciences' Cash from Operations history runs 16 years deep, the most recent figure standing at 7151000.0 for Q4 2025.
- In Q4 2025, Cash from Operations rose 41.0% year-over-year to 7151000.0; the TTM figure through Dec 2025 stood at 34075000.0 (up 4.32% YoY), while the FY2025 annual figure was 39044000.0, down 26.72% from the prior year.
- Cash from Operations came in at 7151000.0 for Q4 2025 at Anavex Life Sciences, up from 8604000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 3500955.0 in Q4 2021 to a low of 12464000.0 in Q2 2025.
- A 5-year average of 7577131.1 and a median of 7317422.5 in 2021 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations soared 55.52% in 2021 and slumped 140.62% in 2025, its largest moves.
- Anavex Life Sciences' Cash from Operations stood at 3500955.0 in 2021, then plunged by 65.5% to 5794000.0 in 2022, then decreased by 26.3% to 7318000.0 in 2023, then slumped by 65.62% to 12120000.0 in 2024, then soared by 41.0% to 7151000.0 in 2025.
- According to Business Quant data, Cash from Operations over the past three periods registered 7151000.0, 8604000.0, and 12464000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | -7.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.15 Mn |
| Dec 31, 2025 | -7.15 Mn |
| Sep 30, 2025 | -8.60 Mn |
| Sep 30, 2025 | -8.60 Mn |
| Jun 30, 2025 | -12.46 Mn |
| Jun 30, 2025 | -12.46 Mn |
| Mar 31, 2025 | -5.86 Mn |
| Mar 31, 2025 | -5.86 Mn |
| Dec 31, 2024 | -12.12 Mn |
| Dec 31, 2024 | -12.12 Mn |
| Sep 30, 2024 | -6.66 Mn |
| Sep 30, 2024 | -6.66 Mn |
| Jun 30, 2024 | -5.18 Mn |
| Jun 30, 2024 | -5.18 Mn |
| Mar 31, 2024 | -11.66 Mn |
| Mar 31, 2024 | -11.66 Mn |
| Dec 31, 2023 | -7.32 Mn |
| Dec 31, 2023 | -7.32 Mn |
| Sep 30, 2023 | -5.85 Mn |
| Sep 30, 2023 | -5.85 Mn |
| Jun 30, 2023 | -7.65 Mn |
| Jun 30, 2023 | -7.65 Mn |
| Mar 31, 2023 | -8.49 Mn |
| Mar 31, 2023 | -8.49 Mn |
| Dec 31, 2022 | -5.79 Mn |
| Dec 31, 2022 | -5.79 Mn |
| Sep 30, 2022 | -4.04 Mn |
| Sep 30, 2022 | -4.04 Mn |
| Jun 30, 2022 | -7.05 Mn |
| Jun 30, 2022 | -7.05 Mn |
| Mar 31, 2022 | -9.64 Mn |
| Mar 31, 2022 | -9.64 Mn |
| Dec 31, 2021 | -3.50 Mn |
| Dec 31, 2021 | -3.50 Mn |
| Sep 30, 2021 | -7.67 Mn |
| Sep 30, 2021 | -7.67 Mn |
| Jun 30, 2021 | -7.52 Mn |
| Jun 30, 2021 | -7.52 Mn |
| Mar 31, 2021 | -7.32 Mn |
| Mar 31, 2021 | -7.32 Mn |
| Dec 31, 2020 | -7.87 Mn |
| Dec 31, 2020 | -7.87 Mn |
| Sep 30, 2020 | -6.25 Mn |
| Sep 30, 2020 | -6.25 Mn |
| Jun 30, 2020 | -4.04 Mn |
| Jun 30, 2020 | -4.04 Mn |
| Mar 31, 2020 | -5.26 Mn |
| Mar 31, 2020 | -5.26 Mn |
| Dec 31, 2019 | -5.73 Mn |
| Dec 31, 2019 | -5.73 Mn |
| Sep 30, 2019 | -2.53 Mn |
| Sep 30, 2019 | -2.53 Mn |
| Jun 30, 2019 | -7.50 Mn |
| Jun 30, 2019 | -7.50 Mn |
| Mar 31, 2019 | -4.33 Mn |
| Mar 31, 2019 | -4.33 Mn |
| Dec 31, 2018 | -4.16 Mn |
| Dec 31, 2018 | -4.16 Mn |
| Sep 30, 2018 | -4.05 Mn |
| Sep 30, 2018 | -4.05 Mn |
| Jun 30, 2018 | -2.09 Mn |
| Jun 30, 2018 | -2.09 Mn |
| Mar 31, 2018 | -2.82 Mn |
| Mar 31, 2018 | -2.82 Mn |
| Dec 31, 2017 | -3.62 Mn |
| Dec 31, 2017 | -3.62 Mn |
| Sep 30, 2017 | -2.19 Mn |
| Sep 30, 2017 | -2.19 Mn |
| Jun 30, 2017 | -2.97 Mn |
| Jun 30, 2017 | -2.97 Mn |
| Mar 31, 2017 | -697,742.00 |
| Mar 31, 2017 | -697,742.00 |
| Dec 31, 2016 | -3.15 Mn |
| Dec 31, 2016 | -3.15 Mn |
| Sep 30, 2016 | -1.86 Mn |
| Sep 30, 2016 | -1.86 Mn |
| Jun 30, 2016 | -2.22 Mn |
| Jun 30, 2016 | -2.22 Mn |
| Mar 31, 2016 | -1.90 Mn |
| Mar 31, 2016 | -1.90 Mn |
| Dec 31, 2015 | -3.25 Mn |
| Dec 31, 2015 | -3.25 Mn |
| Sep 30, 2015 | -1.43 Mn |
| Sep 30, 2015 | -1.43 Mn |
| Jun 30, 2015 | -1.43 Mn |
| Jun 30, 2015 | -1.43 Mn |
| Mar 31, 2015 | -670,281.00 |
| Mar 31, 2015 | -670,281.00 |
| Dec 31, 2014 | -693,070.00 |
| Dec 31, 2014 | -693,070.00 |
| Sep 30, 2014 | -916,855.00 |
| Sep 30, 2014 | -916,855.00 |
| Jun 30, 2014 | -960,005.00 |
| Jun 30, 2014 | -960,005.00 |
| Mar 31, 2014 | -347,529.00 |
| Mar 31, 2014 | -347,529.00 |
| Dec 31, 2013 | -434,990.00 |
| Dec 31, 2013 | -434,990.00 |
| Sep 30, 2013 | -484,508.00 |
| Sep 30, 2013 | -484,508.00 |
| Jun 30, 2013 | -32,190.00 |
| Jun 30, 2013 | -32,190.00 |
| Mar 31, 2013 | -129,302.00 |
| Mar 31, 2013 | -129,302.00 |
| Dec 31, 2012 | -131,573.00 |
| Dec 31, 2012 | -131,573.00 |
| Sep 30, 2012 | -251,933.00 |
| Sep 30, 2012 | -251,933.00 |
| Jun 30, 2012 | -238,702.00 |
| Jun 30, 2012 | -238,702.00 |
| Mar 31, 2012 | -114,182.00 |
| Mar 31, 2012 | -114,182.00 |
| Dec 31, 2011 | -1.09 Mn |
| Dec 31, 2011 | -1.09 Mn |
| Sep 30, 2011 | -922,589.00 |
| Sep 30, 2011 | -922,589.00 |
| Jun 30, 2011 | -1.21 Mn |
| Jun 30, 2011 | -1.21 Mn |
| Mar 31, 2011 | -588,942.00 |
| Mar 31, 2011 | -588,942.00 |
| Dec 31, 2010 | -1.08 Mn |
| Dec 31, 2010 | -1.08 Mn |
| Sep 30, 2010 | -1.66 Mn |
| Sep 30, 2010 | -1.66 Mn |